home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Preventive Drug development: Complexities and Challenges

 
  February 01, 2007  
     
 
Drug Information Association, Doubletree Hotel & Executive Meeting Center, 8120 Wisconsin Avenue, Bethesda, MD, USA
Apr 12 2007


The high cost of disease treatment and the impact that diseases have on the U.S. economy (e.g., loss of productivity) have reached staggering proportions. This will continue as life expectancy increases. Thus, the prevention of illness is essential to controlling healthcare costs. Examples of effective preventative therapies include: the aggressive treatment of hypertension to reduce the risk of stroke, statins to lower cholesterol, the use of low-dose aspirin and beta blockers to prevent death in patients after a myocardial infarction, tamoxifen to reduce the risk of breast cancer, aggressive control of blood glucose to reduce the long-term consequences of diabetes, and most recently, the vaccine against the human papillomavirus, which causes cervical cancer.

This workshop will discuss and explore ways to design disease prevention programs and the complexities and challenges associated with such programs.

 
 
Organized by: Drug Information Association
Invited Speakers: JANET WOODCOCK, MD
Deputy Commissioner and Chief Medical
Officer, FDA.

ROBERT J. TEMPLE, MD
Associate Director for Medical Policy
FDA.

 
Deadline for Abstracts: -
 
Registration: http://www.diahome.org/product/13499/07011.pdf
E-mail: dia@diahome.org
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.